Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KCNN4 | O15554 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464663 | 1.00 | POLB (0.55) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL5455248 | 0.83 | POLB (0.73) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL3278069 | 0.83 | POLB (0.56) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL5455190 | 0.80 | GSK3A (0.74) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL5455188 | 0.80 | GSK3A (0.74) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL7252535 | 0.77 | GSK3A (0.82) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL5461421 | 0.76 | KCNN4 (0.65) | POLBGSK3AGSK3BKCNN4ALDH1A1 | |
| SCHEMBL5468557 | 0.75 | ALDH1A1 (0.52) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL6693108 | 0.74 | GSK3A (0.59) | POLBGSK3AGSK3BHDAC1HDAC6 | |
| SCHEMBL1555025 | 0.72 | GSK3A (0.70) | POLBGSK3AGSK3BHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | POLB 3236/4885GSK3A 2857/4885GSK3B 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.